SCHEMBL1967582

SCHEMBL1967582

CCCc1cc2c(N3CCn4c(nnc4C(F)(F)F)C3)nc(N3CCOCC3)nc2s1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 6/20 0.68
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTR6 P50406 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 2/20 0.34
HPGD P15428 2/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
PIK3CA P42336 5/20 0.33
PIK3R1 P27986 3/20 0.33
PIK3CB P42338 2/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974132 0.94 P2RY12 (0.73) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL12491713 0.93 P2RY12 (0.70) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL1969002 0.92 P2RY12 (0.69) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL1969201 0.90 P2RY12 (0.67) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL1972915 0.89 P2RY12 (0.64) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL1965731 0.89 P2RY12 (0.64) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL1967498 0.89 P2RY12 (0.65) P2RY12MEN1KMT2AHTR6
SCHEMBL1968619 0.89 P2RY12 (0.65) P2RY12MEN1KMT2AHTR6
SCHEMBL12409380 0.89 P2RY12 (0.65) P2RY12MEN1KMT2AHTR6KDM4E
SCHEMBL1966794 0.89 P2RY12 (0.65) P2RY12MEN1KMT2AHTR6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 P2RY12 127/4885MEN1 849/4885KMT2A 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.